Johnson & Johnson reports positive phase 2b results for experimental IBD therapy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. GOOGL
5. APGE
6. MU
7. USO
8. HOOD
9. DFTX
10. RGNX

Go back to Johnson & Johnson reports positive phase 2b results for experimental IBD therapy
Johnson & Johnson (NYSE: JNJ) Delayed: 231.08 +2.69 (1.18%)
Previous Close $228.39    52 Week High $126.07 
Open $228.95    52 Week Low $94.28 
Day High $231.45    P/E 48.04 
Day Low $227.50    EPS $4.81 
Volume 2,523,207